Docetaxel + Pembrolizumab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Effect of Drug
Conditions
Effect of Drug
Trial Timeline
Jul 6, 2022 → Nov 30, 2025
NCT ID
NCT05252429About Docetaxel + Pembrolizumab
Docetaxel + Pembrolizumab is a phase 2 stage product being developed by Merck for Effect of Drug. The current trial status is active. This product is registered under clinical trial identifier NCT05252429. Target conditions include Effect of Drug.
What happened to similar drugs?
2 of 4 similar drugs in Effect of Drug were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05252429 | Phase 2 | Active |
Competing Products
20 competing products in Effect of Drug